Leflunomida Viatris

Leflunomide, the active ingredient in Leflunomida Viatris, is a disease-modifying antirheumatic drug (DMARD) presented as an oral tablet for oral use. It is used to treat rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomida Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers, with a focus on regulatory compliance and timely delivery to support patient needs across diverse markets.

Leflunomida Viatris, a disease-modifying antirheumatic drug (DMARD), is approved for the treatment of inflammatory joint disorders that cause chronic pain, swelling, and progressive joint damage. - Rheumatoid arthritis: helps decrease joint inflammation, pain, and swelling, and can slow structural damage and functional decline in adult patients with moderate to severe disease. - Psoriatic arthritis: alleviates joint pain and swelling while also addressing associated skin lesions, contributing to improved physical function and quality of life in adults with active disease.

Leflunomida Viatris may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Diarrhoea: mild to moderate loose stools. - Nausea: occasional feeling of sickness. - Elevated liver enzymes: transient increase in ALT/AST. - Hypertension: rise in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone marrow suppression: neutropenia, anaemia, thrombocytopenia. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should consider several safety measures. - Liver function monitoring: assess baseline and periodic ALT/AST levels. - Blood count monitoring: perform regular complete blood counts to detect cytopenias. - Pregnancy contraindication: avoid use in women who are pregnant or may become pregnant; effective contraception required. - Infection risk: monitor for signs of infection and delay treatment if active infection is present. - Drug interactions: review concomitant medications that may affect hepatic metabolism. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight in the original container.

Leflunomida Viatris can interact with several medicines, necessitating careful review.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect may raise INR. - Methotrexate: additive hepatotoxicity risk. - Live vaccines: heightened risk of infection; avoid concurrent administration.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise leflunomide plasma levels. - Statins: possible increased risk of myopathy. - NSAIDs: may exacerbate hypertension or renal impairment.